Richard M Goldberg MD

Richard M Goldberg MD
ProfessorCollege of
Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
  • Experimental Therapeutics

Current Publications

  • Goldberg RMProstate cancer incidence in males with Lynch syndrome.Genet Med 1/16/2014
  • McLeod HGermline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer.PLoS One 9 e94727 1/1/2014
  • Alberts SRComparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147.Clin Colorectal Cancer 12/28/2013
  • Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HIPrognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).Clin Cancer Res 19 6957-66 12/15/2013
  • Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB 3rd, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CSPredictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial.J Natl Cancer Inst 105 1789-98 12/4/2013
  • Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MMUGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.Invest New Drugs 31 1559-67 12/1/2013
  • Warren RS, Atreya CE, Niedzwiecki D, Weinberg V, Donner DB, Mayer RJ, Goldberg RM, Compton C, Zuraek MB, Ye X, Saltz LB, Bertagnolli MMAssociation of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.Clin Cancer Res 19 5777-87 10/15/2013
  • Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SRPrognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.J Clin Oncol 31(29) 3664-72 10/10/2013
  • Goldberg RMHow we treat metastatic colon cancer in older adults.J Geriatr Oncol 4(4) 295-301 10/1/2013
  • Garrett CR, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, Kavan P, Shacham-Shmueli E, Buchbinder A, Goldberg RMRandomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.Cancer in press 9/16/2013
  • Haraldsdottir S, Wu C, Bloomston M, Goldberg RMWhat is the optimal neo-adjuvant treatment for liver metastasis?Ther Adv Med Oncol 5(4) 221-34 7/1/2013
  • Van Loon K, Wigler D, Niedzwiecki D, Venook AP, Fuchs C, Blanke C, Saltz L, Goldberg RM, Meyerhardt JAComparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405.Clin Colorectal Cancer 12(2) 95-102 6/1/2013
  • Raftery L, Tepper JE, Goldberg RM, Blackstock AW, Aklilu M, Bernard SA, Ivanova A, Davies JM, O'Neil BHA two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.Am J Clin Oncol 36(3) 250-3 6/1/2013
  • Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MMBiologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.J Clin Oncol 31(14) 1775-81 5/10/2013
  • Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, Goldberg RM, Degramont A, O'Connell MJ, Sargent DJBody mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.Cancer 119(8) 1528-36 4/15/2013
  • Wu C, Goldberg RMColorectal cancer in 2012: Revisiting landmark trials and identifying new therapies.Nat Rev Clin Oncol 10(2) 71-2 2/1/2013
  • Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent DRegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet 381(9863) 303-12 1/26/2013
  • Wu C, Goldberg RMManaging choices for older patients with colon cancer.Am Soc Clin Oncol Educ Book 2013 190-3 1/1/2013
  • Bekaii-Saab T, Goldberg RMFOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?Oncologist 18(5) 487-9 1/1/2013
  • Sugihara K, Ohtsu A, Shimada Y, Mizunuma N, Gomi K, Lee PH, Gramont A, Rothenberg ML, André T, Brienza S, Goldberg RMAnalysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.Cancer Med 1(2) 198-206 10/1/2012
  • Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, Schrag DComparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.Cancer 118(17) 4309-20 9/1/2012
  • Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag DEffect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.J Clin Oncol 30(21) 2624-34 7/20/2012
  • Vijayaraghavan A, Efrusy MB, Göke B, Kirchner T, Santas CC, Goldberg RMCost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.Int J Cancer 131(2) 438-45 7/15/2012
  • Sugihara K, Ohtsu A, Shimada Y, Mizunuma N, Lee PH, de Gramont A, Goldberg RM, Rothenberg ML, André T, Brienza S, Gomi KSafety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.Clin Colorectal Cancer 11(2) 127-37 6/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: